Status:
COMPLETED
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
Lead Sponsor:
Baylor College of Medicine
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
National Center for Research Resources (NCRR)
Conditions:
Major Depression
Eligibility:
All Genders
21-70 years
Phase:
PHASE4
Brief Summary
This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine th...
Detailed Description
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ke...
Eligibility Criteria
Inclusion
- Male or female patients, 21- 70 years of age
- Subjects have a history of at least one previous episode of depression prior to the current episode (recurrent major depressive disorder) or have chronic major depressive disorder (at least two years' duration)
- Subjects have not responded to an adequate trial of one antidepressant in the current episode
Exclusion
- Female subjects who are either pregnant or nursing
- Serious, unstable illnesses
- Any previous use or treatment with ketamine, or riluzole
- Past intolerance to lamotrigine, including drug rash
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00419003
Start Date
December 1 2006
End Date
September 1 2008
Last Update
July 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai School of Medicine
New York, New York, United States, 10029